Six China-based companies—Porton Advanced Solutions Ltd, Shanghai Sequanta Biological Technology Co., Ltd, QuaCell Biotechnology Co., Ltd, EurekaBio Technology Co., Ltd, SAFE Pharmaceutical Technology Co., Ltd, and SanQ (Beijing) Biotechnology Co., Ltd—have formed a strategic partnership in the cell and gene therapy (CGT) sector. The collaboration aims to create a comprehensive CGT ecosystem, fostering coordinated development across the industry chain and offering whole life-cycle drug development services.
Partnership Details
- QuaCell Biotechnology: Specializes in manufacturing culture media and cell lines for key raw materials.
- EurekaBio Technology: Focuses on developing lentiviral vectors and fully enclosed automated cell processing systems.
- Shanghai Sequanta Biological Technology: Provides multi-omics analysis services to support drug development.
- Porton Advanced Solutions: Offers end-to-end gene and cell therapy CDMO services, covering process development to commercial production.
- SAFE Pharmaceutical Technology: Provides one-stop CRO services for drug preclinical and clinical trials.
- SanQ (Beijing) Biotechnology: Supports IND filing and regulatory consultation services.
Strategic Outlook
The partnership is expected to accelerate innovation in CGT by integrating each firm’s expertise, enabling seamless development from research to commercialization. The collaborative model aims to address unmet needs in the CGT sector, with a focus on enhancing therapeutic outcomes and operational efficiency.-Fineline Info & Tech
